CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: These results were cross-referenced with a patient dataset (E-MTAB-2594), obtained from CML CD34+ cells treated with imatinib for 7 days44, where a higher proportion of expressed genes were significantly different (10,762: 56%) (Supplementary Fig. S2E).